Longitudinal changes in adiponectin and inflammatory markers and relation to survival in the oldest old: the Cardiovascular Health Study All Stars study.

BACKGROUND Adiponectin has anti-inflammatory properties, and its production is suppressed by inflammatory factors. Although elevated levels of adiponectin and inflammatory markers each predict mortality in older adults, the implications of their interdependent actions have not been examined. METHODS We investigated the joint associations of levels and interval changes in adiponectin, C-reactive protein (CRP), and interleukin 6 (IL-6) with risk of death in 840 older adults participating in a population-based study. Adiponectin, CRP, and IL-6 were measured in samples collected 8.9 (8.2-9.8) years apart, and all-cause mortality was subsequently ascertained (n = 176). RESULTS Interval changes and end levels of adiponectin, CRP, and IL-6 showed mostly positive, independent associations with mortality, without evidence of multiplicative interaction. Joint models, however, showed an U-shaped relationship between end level of adiponectin and outcome (hazard ratio [HR] [95% CI] = 0.72 [0.52-0.99] per standard deviation [SD] for levels <20.0 mg/L; HR = 1.91 [1.61-3.44] per SD for levels ≥20.0 mg/L). Participants with the greatest longitudinal increases (upper quartile) in both adiponectin and inflammatory markers had a higher risk of death (HR = 2.85 [1.78-4.58]) than those with large increases in adiponectin alone (HR = 1.87 [1.20-2.92]) (p = .043), but not inflammatory markers alone (HR = 2.48 [1.67-3.67]) (p = .55), as compared with smaller changes for both. CONCLUSION Higher levels or interval change in adiponectin and inflammatory markers predict increased mortality in older persons independent of each other, although for adiponectin, the association appears inverse below 20 mg/L. These findings suggest that inflammatory and noninflammatory mechanisms governing aging-related decline operate in parallel and provide a potential explanation for paradoxical adiponectin-outcome associations reported previously.

[1]  S. Kritchevsky,et al.  Change in circulating adiponectin in advanced old age: determinants and impact on physical function and mortality. The Cardiovascular Health Study All Stars Study. , 2010, The journals of gerontology. Series A, Biological sciences and medical sciences.

[2]  P. Libby,et al.  Adiponectin Inhibits Pro-inflammatory Signaling in Human Macrophages Independent of Interleukin-10* , 2009, The Journal of Biological Chemistry.

[3]  L. Fried,et al.  Long‐Term Function in an Older Cohort—The Cardiovascular Health Study All Stars Study , 2009, Journal of the American Geriatrics Society.

[4]  S. Anton,et al.  Molecular inflammation: Underpinnings of aging and age-related diseases , 2009, Ageing Research Reviews.

[5]  S. Cummings,et al.  Association of adiponectin with mortality in older adults: the Health, Aging, and Body Composition Study , 2009, Diabetologia.

[6]  L. Kuller,et al.  Adiponectin and risk of coronary heart disease in older men and women. , 2008, Journal of Clinical Endocrinology and Metabolism.

[7]  R. Lipton,et al.  Adiponectin levels and genotype: a potential regulator of life span in humans. , 2008, The journals of gerontology. Series A, Biological sciences and medical sciences.

[8]  L. Ferrucci,et al.  Three‐Year Change in Inflammatory Markers in Elderly People and Mortality: The Invecchiare in Chianti Study , 2007, Journal of the American Geriatrics Society.

[9]  U. Smith,et al.  Culprit Underlying the Metabolic Syndrome and Atherosclerosis , 2007 .

[10]  P. Whincup,et al.  Circulating adiponectin levels and mortality in elderly men with and without cardiovascular disease and heart failure. , 2007, Archives of internal medicine.

[11]  S. Kihara,et al.  Adiponectin modulates inflammatory reactions via calreticulin receptor-dependent clearance of early apoptotic bodies. , 2007, The Journal of clinical investigation.

[12]  G. Castellani,et al.  Inflammaging and anti-inflammaging: A systemic perspective on aging and longevity emerged from studies in humans , 2007, Mechanisms of Ageing and Development.

[13]  E. Barrett-Connor,et al.  Association of adiponectin with coronary heart disease and mortality: the Rancho Bernardo study. , 2006, American journal of epidemiology.

[14]  George A Mensah,et al.  CDC/AHA Workshop on Markers of Inflammation and Cardiovascular Disease: Application to Clinical and Public Health Practice: overview. , 2004, Circulation.

[15]  S. Toubro,et al.  Regulation of adiponectin by adipose tissue-derived cytokines: in vivo and in vitro investigations in humans. , 2003, American journal of physiology. Endocrinology and metabolism.

[16]  Sidney C. Smith,et al.  MARKERS OF INFLAMMATION AND CARDIOVASCULAR DISEASE: APPLICATION TO CLINICAL AND PUBLIC HEALTH PRACTICE: A STATEMENT FOR HEALTHCARE PROFESSIONALS FROM THE CENTERS FOR DISEASE CONTROL AND PREVENTION AND THE AMERICAN HEART ASSOCIATION , 2003 .

[17]  Gary L Myers,et al.  Markers of inflammation and cardiovascular disease: application to clinical and public health practice: A statement for healthcare professionals from the Centers for Disease Control and Prevention and the American Heart Association. , 2003, Circulation.

[18]  S. Kihara,et al.  Adiponectin, an Adipocyte-Derived Plasma Protein, Inhibits Endothelial NF-&kgr;B Signaling Through a cAMP-Dependent Pathway , 2000, Circulation.

[19]  H. Cohen,et al.  Associations of elevated interleukin-6 and C-reactive protein levels with mortality in the elderly. , 1999, The American journal of medicine.

[20]  L H Kuller,et al.  Surveillance and ascertainment of cardiovascular events. The Cardiovascular Health Study. , 1995, Annals of epidemiology.

[21]  L. Kuller,et al.  Methods of assessing prevalent cardiovascular disease in the Cardiovascular Health Study. , 1995, Annals of epidemiology.

[22]  M. Cushman,et al.  Laboratory methods and quality assurance in the Cardiovascular Health Study. , 1995, Clinical chemistry.

[23]  R. Kronmal,et al.  The Cardiovascular Health Study: design and rationale. , 1991, Annals of epidemiology.

[24]  C. Mantzoros,et al.  Adiponectin in insulin resistance: lessons from translational research. , 2010, The American journal of clinical nutrition.

[25]  Vicente Bertomeu Martínez,et al.  Markers of Inflammation and Cardiovascular Disease , 2009, American journal of cardiovascular drugs : drugs, devices, and other interventions.

[26]  M. Bots,et al.  rediction of Mortality Risk in the Elderly , 2006 .

[27]  R. Tracy,et al.  Variability in the measurement of C-reactive protein in healthy subjects: implications for reference intervals and epidemiological applications. , 1997, Clinical chemistry.